ID   PTN22_HUMAN             Reviewed;         807 AA.
AC   Q9Y2R2; A0N0K6; B1ALC8; D4NZ71; E9PLD8; E9PPI1; O95063; O95064; Q6IPX8;
AC   Q8WVM1;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 2.
DT   28-JAN-2026, entry version 202.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 22;
DE            EC=3.1.3.48 {ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:27043286};
DE   AltName: Full=Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP;
DE   AltName: Full=Lymphoid phosphatase;
DE            Short=LyP;
DE   AltName: Full=PEST-domain phosphatase;
DE            Short=PEP;
GN   Name=PTPN22; Synonyms=PTPN8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND INTERACTION WITH CBL.
RX   PubMed=10068674;
RA   Cohen S., Dadi H., Shaoul E., Sharfe N., Roifman C.M.;
RT   "Cloning and characterization of a lymphoid-specific, inducible human
RT   protein tyrosine phosphatase, Lyp.";
RL   Blood 93:2013-2024(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT TRP-620.
RX   PubMed=21044313; DOI=10.1186/1471-2199-11-78;
RA   Wang S., Dong H., Han J., Ho W.T., Fu X., Zhao Z.J.;
RT   "Identification of a variant form of tyrosine phosphatase LYP.";
RL   BMC Mol. Biol. 11:78-78(2010).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TRP-620.
RA   Liu T., Zhang J., Fu G., Zhang Q., Ye M., Zhou J., Wu J., Shen Y., Yu M.,
RA   Chen S., Mao M., Chen Z.;
RT   "Human protein tyrosine phosphatase (70zpep) homolog.";
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-620.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-620.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=16461343; DOI=10.1074/jbc.m600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J., Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=17729039; DOI=10.1080/08916930701464897;
RA   Vang T., Miletic A.V., Bottini N., Mustelin T.;
RT   "Protein tyrosine phosphatase PTPN22 in human autoimmunity.";
RL   Autoimmunity 40:453-461(2007).
RN   [11]
RP   ALTERNATIVE SPLICING (ISOFORM 6).
RX   PubMed=22427951; DOI=10.1371/journal.pone.0033067;
RA   Chang H.H., Tai T.S., Lu B., Iannaccone C., Cernadas M., Weinblatt M.,
RA   Shadick N., Miaw S.C., Ho I.C.;
RT   "PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of
RT   rheumatoid arthritis.";
RL   PLoS ONE 7:E33067-E33067(2012).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TRAF3.
RX   PubMed=23871208; DOI=10.1016/j.immuni.2013.06.013;
RA   Wang Y., Shaked I., Stanford S.M., Zhou W., Curtsinger J.M., Mikulski Z.,
RA   Shaheen Z.R., Cheng G., Sawatzke K., Campbell A.M., Auger J.L., Bilgic H.,
RA   Shoyama F.M., Schmeling D.O., Balfour H.H. Jr., Hasegawa K., Chan A.C.,
RA   Corbett J.A., Binstadt B.A., Mescher M.F., Ley K., Bottini N.,
RA   Peterson E.J.;
RT   "The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-
RT   driven, type 1 interferon-dependent immunity.";
RL   Immunity 39:111-122(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-449, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION.
RX   PubMed=23991106; DOI=10.1371/journal.pone.0072384;
RA   Spalinger M.R., Lang S., Vavricka S.R., Fried M., Rogler G., Scharl M.;
RT   "Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-induced
RT   cytokine release and autophagy.";
RL   PLoS ONE 8:E72384-E72384(2013).
RN   [15]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27043286; DOI=10.1172/jci83669;
RA   Spalinger M.R., Kasper S., Gottier C., Lang S., Atrott K., Vavricka S.R.,
RA   Scharl S., Raselli T., Frey-Wagner I., Gutte P.M., Gruetter M.G.,
RA   Beer H.D., Contassot E., Chan A.C., Dai X., Rawlings D.J., Mair F.,
RA   Becher B., Falk W., Fried M., Rogler G., Scharl M.;
RT   "NLRP3 tyrosine phosphorylation is controlled by protein tyrosine
RT   phosphatase PTPN22.";
RL   J. Clin. Invest. 126:1783-1800(2016).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-294 IN COMPLEX WITH INHIBITOR,
RP   FUNCTION, PHOSPHORYLATION AT SER-35, AND MUTAGENESIS OF SER-35 AND THR-36.
RX   PubMed=18056643; DOI=10.1073/pnas.0706233104;
RA   Yu X., Sun J.P., He Y., Guo X., Liu S., Zhou B., Hudmon A., Zhang Z.Y.;
RT   "Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific
RT   tyrosine phosphatase implicated in autoimmune diseases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:19767-19772(2007).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-302, DISULFIDE BOND, AND
RP   MUTAGENESIS OF CYS-129 AND CYS-231.
RX   PubMed=19371084; DOI=10.1021/bi900166y;
RA   Tsai S.J., Sen U., Zhao L., Greenleaf W.B., Dasgupta J., Fiorillo E.,
RA   Orru V., Bottini N., Chen X.S.;
RT   "Crystal structure of the human lymphoid tyrosine phosphatase catalytic
RT   domain: insights into redox regulation.";
RL   Biochemistry 48:4838-4845(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1-302, AND FUNCTION.
RX   PubMed=19167335; DOI=10.1016/j.cell.2008.11.038;
RA   Barr A.J., Ugochukwu E., Lee W.H., King O.N.F., Filippakopoulos P.,
RA   Alfano I., Savitsky P., Burgess-Brown N.A., Mueller S., Knapp S.;
RT   "Large-scale structural analysis of the classical human protein tyrosine
RT   phosphatome.";
RL   Cell 136:352-363(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 2-309 OF WILD TYPE AND VARIANT
RP   GLN-263, VARIANT GLN-263, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF
RP   VARIANT GLN-263.
RX   PubMed=18981062; DOI=10.1093/hmg/ddn363;
RA   Orru V., Tsai S.J., Rueda B., Fiorillo E., Stanford S.M., Dasgupta J.,
RA   Hartiala J., Zhao L., Ortego-Centeno N., D'Alfonso S., Arnett F.C., Wu H.,
RA   Gonzalez-Gay M.A., Tsao B.P., Pons-Estel B., Alarcon-Riquelme M.E., He Y.,
RA   Zhang Z.Y., Allayee H., Chen X.S., Martin J., Bottini N., Danieli M.G.,
RA   Galeazzi M., Sabbadini M.G., Migliaresi S., Sebastiani G.D.;
RT   "A loss-of-function variant of PTPN22 is associated with reduced risk of
RT   systemic lupus erythematosus.";
RL   Hum. Mol. Genet. 18:569-579(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-310 IN COMPLEX WITH SUBSTRATE.
RA   Seidel R.D., Love J., Piserchio A., Cowburn D.;
RT   "Lyp/PTPN22 phosphatase domain: substrate recognition and specificity for
RT   Src family kinases.";
RL   Submitted (DEC-2009) to the PDB data bank.
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-294 OF MUTANT SER-227 ALONE AND
RP   IN COMPLEX WITH SKAP2 PEPTIDE, SUBSTRATE SPECIFICITY, AND FUNCTION.
RX   PubMed=21719704; DOI=10.1074/jbc.m111.254722;
RA   Yu X., Chen M., Zhang S., Yu Z.H., Sun J.P., Wang L., Liu S., Imasaki T.,
RA   Takagi Y., Zhang Z.Y.;
RT   "Substrate specificity of lymphoid-specific tyrosine phosphatase (Lyp) and
RT   identification of Src kinase-associated protein of 55 kDa homolog (SKAP-
RT   HOM) as a Lyp substrate.";
RL   J. Biol. Chem. 286:30526-30534(2011).
RN   [22]
RP   VARIANT TRP-620, INVOLVEMENT IN RA, INTERACTION WITH CSK, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15208781; DOI=10.1086/422827;
RA   Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J.,
RA   Chokkalingam A.P., Alexander H.C., Ardlie K.G., Huang Q., Smith A.M.,
RA   Spoerke J.M., Conn M.T., Chang M., Chang S.Y., Saiki R.K., Catanese J.J.,
RA   Leong D.U., Garcia V.E., McAllister L.B., Jeffery D.A., Lee A.T.,
RA   Batliwalla F., Remmers E., Criswell L.A., Seldin M.F., Kastner D.L.,
RA   Amos C.I., Sninsky J.J., Gregersen P.K.;
RT   "A missense single-nucleotide polymorphism in a gene encoding a protein
RT   tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.";
RL   Am. J. Hum. Genet. 75:330-337(2004).
RN   [23]
RP   VARIANT TRP-620, AND INVOLVEMENT IN SLE.
RX   PubMed=15273934; DOI=10.1086/423790;
RA   Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S., Carlton V.E.H.,
RA   Chang M., Ramos P., Baechler E.C., Batliwalla F.M., Novitzke J.,
RA   Williams A.H., Gillett C., Rodine P., Graham R.R., Ardlie K.G.,
RA   Gaffney P.M., Moser K.L., Petri M., Begovich A.B., Gregersen P.K.,
RA   Behrens T.W.;
RT   "Genetic association of the R620W polymorphism of protein tyrosine
RT   phosphatase PTPN22 with human SLE.";
RL   Am. J. Hum. Genet. 75:504-507(2004).
RN   [24]
RP   VARIANT TRP-620, INVOLVEMENT IN T1D, AND CHARACTERIZATION OF VARIANT
RP   TRP-620.
RX   PubMed=15004560; DOI=10.1038/ng1323;
RA   Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M.,
RA   MacMurray J., Meloni G.F., Lucarelli P., Pellecchia M., Eisenbarth G.S.,
RA   Comings D., Mustelin T.;
RT   "A functional variant of lymphoid tyrosine phosphatase is associated with
RT   type I diabetes.";
RL   Nat. Genet. 36:337-338(2004).
RN   [25]
RP   VARIANT TRP-620.
RX   PubMed=15531553; DOI=10.1210/jc.2004-1108;
RA   Velaga M.R., Wilson V., Jennings C.E., Owen C.J., Herington S.,
RA   Donaldson P.T., Ball S.G., James R.A., Quinton R., Perros P., Pearce S.H.;
RT   "The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP)
RT   gene is a major determinant of Graves' disease.";
RL   J. Clin. Endocrinol. Metab. 89:5862-5865(2004).
RN   [26]
RP   VARIANT TRP-620.
RX   PubMed=15719322; DOI=10.1086/429096;
RA   Criswell L.A., Pfeiffer K.A., Lum R.F., Gonzales B., Novitzke J., Kern M.,
RA   Moser K.L., Begovich A.B., Carlton V.E., Li W., Lee A.T., Ortmann W.,
RA   Behrens T.W., Gregersen P.K.;
RT   "Analysis of families in the multiple autoimmune disease genetics
RT   consortium (MADGC) collection: the PTPN22 620W allele associates with
RT   multiple autoimmune phenotypes.";
RL   Am. J. Hum. Genet. 76:561-571(2005).
RN   [27]
RP   VARIANT TRP-620, AND INVOLVEMENT IN VTLG.
RX   PubMed=16015369; DOI=10.1038/sj.gene.6364243;
RA   Canton I., Akhtar S., Gavalas N.G., Gawkrodger D.J., Blomhoff A.,
RA   Watson P.F., Weetman A.P., Kemp E.H.;
RT   "A single-nucleotide polymorphism in the gene encoding lymphoid protein
RT   tyrosine phosphatase (PTPN22) confers susceptibility to generalised
RT   vitiligo.";
RL   Genes Immun. 6:584-587(2005).
RN   [28]
RP   VARIANT TRP-620, AND CHARACTERIZATION OF VARIANT TRP-620.
RX   PubMed=19265110; DOI=10.4049/jimmunol.0713370;
RA   Arechiga A.F., Habib T., He Y., Zhang X., Zhang Z.Y., Funk A.,
RA   Buckner J.H.;
RT   "Cutting edge: the PTPN22 allelic variant associated with autoimmunity
RT   impairs B cell signaling.";
RL   J. Immunol. 182:3343-3347(2009).
RN   [29]
RP   VARIANTS GLN-263 AND TRP-620, AND CHARACTERIZATION OF VARIANTS GLN-263 AND
RP   TRP-620.
RX   PubMed=21287672; DOI=10.1002/ibd.21630;
RA   Diaz-Gallo L.M., Espino-Paisan L., Fransen K., Gomez-Garcia M.,
RA   van Sommeren S., Cardena C., Rodrigo L., Mendoza J.L., Taxonera C.,
RA   Nieto A., Alcain G., Cueto I., Lopez-Nevot M.A., Bottini N., Barclay M.L.,
RA   Crusius J.B., van Bodegraven A.A., Wijmenga C., Ponsioen C.Y., Gearry R.B.,
RA   Roberts R.L., Weersma R.K., Urcelay E., Merriman T.R., Alizadeh B.Z.,
RA   Martin J.;
RT   "Differential association of two PTPN22 coding variants with Crohn's
RT   disease and ulcerative colitis.";
RL   Inflamm. Bowel Dis. 17:2287-2294(2011).
RN   [30]
RP   VARIANTS PHE-201; GLN-263 AND TRP-266, AND CHARACTERIZATION OF VARIANTS
RP   PHE-201; GLN-263 AND TRP-266.
RX   PubMed=22952725; DOI=10.1371/journal.pone.0043631;
RA   Liu J., Chen M., Li R., Yang F., Shi X., Zhu L., Wang H.M., Yao W., Liu Q.,
RA   Meng F.G., Sun J.P., Pang Q., Yu X.;
RT   "Biochemical and functional studies of lymphoid-specific tyrosine
RT   phosphatase (Lyp) variants S201F and R266W.";
RL   PLoS ONE 7:E43631-E43631(2012).
CC   -!- FUNCTION: Acts as a negative regulator of T-cell receptor (TCR)
CC       signaling by direct dephosphorylation of the Src family kinases LCK and
CC       FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and
CC       other key signaling molecules (PubMed:16461343, PubMed:18056643).
CC       Associates with and probably dephosphorylates CBL. Dephosphorylates LCK
CC       at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates
CC       ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343).
CC       Dephosphorylates the immune system activator SKAP2 (PubMed:21719704).
CC       Positively regulates toll-like receptor (TLR)-induced type 1 interferon
CC       production (PubMed:23871208). Promotes host antiviral responses
CC       mediated by type 1 interferon (By similarity). Regulates NOD2-induced
CC       pro-inflammatory cytokine secretion and autophagy (PubMed:23991106).
CC       Acts as an activator of NLRP3 inflammasome assembly by mediating
CC       dephosphorylation of 'Tyr-861' of NLRP3 (PubMed:27043286).
CC       Dephosphorylates phospho-anandamide (p-AEA), an endocannabinoid to
CC       anandamide (also called N-arachidonoylethanolamide) (By similarity).
CC       {ECO:0000250|UniProtKB:P29352, ECO:0000269|PubMed:16461343,
CC       ECO:0000269|PubMed:18056643, ECO:0000269|PubMed:19167335,
CC       ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:23871208,
CC       ECO:0000269|PubMed:23991106, ECO:0000269|PubMed:27043286}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044, ECO:0000269|PubMed:21719704,
CC         ECO:0000269|PubMed:27043286};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine phosphate +
CC         H2O = N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine + phosphate;
CC         Xref=Rhea:RHEA:56532, ChEBI:CHEBI:2700, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:131894;
CC         Evidence={ECO:0000250|UniProtKB:P29352};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:56533;
CC         Evidence={ECO:0000250|UniProtKB:P29352};
CC   -!- ACTIVITY REGULATION: Down-regulated by phosphorylation.
CC   -!- SUBUNIT: Interacts with CSK (PubMed:15208781). Interacts with LPXN (By
CC       similarity). Interacts with CBL (PubMed:10068674). Interacts with TRAF3
CC       (via MATH domain); the interaction promotes TRAF3 polyubiquitination
CC       (PubMed:23871208). {ECO:0000250|UniProtKB:P29352,
CC       ECO:0000269|PubMed:10068674, ECO:0000269|PubMed:15208781,
CC       ECO:0000269|PubMed:18056643, ECO:0000269|PubMed:21719704,
CC       ECO:0000269|PubMed:23871208, ECO:0000269|Ref.20}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P29352}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=LyP1;
CC         IsoId=Q9Y2R2-1; Sequence=Displayed;
CC       Name=2; Synonyms=LyP2;
CC         IsoId=Q9Y2R2-2; Sequence=VSP_005134;
CC       Name=3;
CC         IsoId=Q9Y2R2-3; Sequence=VSP_039728;
CC       Name=4; Synonyms=LYP3;
CC         IsoId=Q9Y2R2-4; Sequence=VSP_039729;
CC       Name=5;
CC         IsoId=Q9Y2R2-5; Sequence=VSP_039725, VSP_039726, VSP_039727;
CC       Name=6; Synonyms=PTPN22.6;
CC         IsoId=Q9Y2R2-6; Sequence=VSP_044428, VSP_044429;
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow, B and T-cells, PBMCs,
CC       natural killer cells, monocytes, dendritic cells and neutrophils
CC       (PubMed:15208781). Both isoform 1 and 4 are predominantly expressed in
CC       lymphoid tissues and cells. Isoform 1 is expressed in thymocytes and
CC       both mature B and T-cells. {ECO:0000269|PubMed:15208781}.
CC   -!- INDUCTION: By muramyl-dipeptide and lipopolysaccharide.
CC       {ECO:0000269|PubMed:23991106}.
CC   -!- PTM: Phosphorylation on Ser-35 by PKC/PRKCD abrogates its ability to
CC       dephosphorylate and inactivate the SRC family kinases.
CC       {ECO:0000269|PubMed:18056643}.
CC   -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic,
CC       relapsing, inflammatory, and often febrile multisystemic disorder of
CC       connective tissue, characterized principally by involvement of the
CC       skin, joints, kidneys and serosal membranes. It is of unknown etiology,
CC       but is thought to represent a failure of the regulatory mechanisms of
CC       the autoimmune system. The disease is marked by a wide range of system
CC       dysfunctions, an elevated erythrocyte sedimentation rate, and the
CC       formation of LE cells in the blood or bone marrow.
CC       {ECO:0000269|PubMed:15273934}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Type 1 diabetes mellitus (T1D) [MIM:222100]: A multifactorial
CC       disorder of glucose homeostasis that is characterized by susceptibility
CC       to ketoacidosis in the absence of insulin therapy. Clinical features
CC       are polydipsia, polyphagia and polyuria which result from
CC       hyperglycemia-induced osmotic diuresis and secondary thirst. These
CC       derangements result in long-term complications that affect the eyes,
CC       kidneys, nerves, and blood vessels. {ECO:0000269|PubMed:15004560}.
CC       Note=Disease susceptibility may be associated with variants affecting
CC       the gene represented in this entry.
CC   -!- DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory
CC       disease with autoimmune features and a complex genetic component. It
CC       primarily affects the joints and is characterized by inflammatory
CC       changes in the synovial membranes and articular structures, widespread
CC       fibrinoid degeneration of the collagen fibers in mesenchymal tissues,
CC       and by atrophy and rarefaction of bony structures.
CC       {ECO:0000269|PubMed:15208781}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Vitiligo (VTLG) [MIM:193200]: A pigmentary disorder of the
CC       skin and mucous membranes. It is characterized by circumscribed
CC       depigmented macules and patches, commonly on extensor aspects of
CC       extremities, on the face or neck and in skin folds. Vitiligo is a
CC       progressive disorder in which some or all of the melanocytes in the
CC       affected skin are selectively destroyed. It is a multifactorial
CC       disorder with a complex etiology probably including autoimmune
CC       mechanisms, and is associated with an elevated risk of other autoimmune
CC       diseases. {ECO:0000269|PubMed:16015369}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Due to intron retention. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Lacks most of the phosphatase domain and
CC       functions as a dominant negative isoform of the full length PTPN22.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family. Non-
CC       receptor class 4 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF001846; AAD00904.1; -; mRNA.
DR   EMBL; AF001847; AAD00905.1; -; mRNA.
DR   EMBL; GU479452; ADD59979.1; -; mRNA.
DR   EMBL; AF077031; AAD27764.1; -; mRNA.
DR   EMBL; AK310570; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; EF064714; ABK41897.1; -; Genomic_DNA.
DR   EMBL; AL137856; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471122; EAW56575.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56576.1; -; Genomic_DNA.
DR   EMBL; BC017785; AAH17785.1; -; mRNA.
DR   EMBL; BC071670; AAH71670.1; -; mRNA.
DR   CCDS; CCDS863.1; -. [Q9Y2R2-1]
DR   CCDS; CCDS864.2; -. [Q9Y2R2-3]
DR   RefSeq; NP_001295226.2; NM_001308297.2.
DR   PDB; 2P6X; X-ray; 1.90 A; A/B=1-302.
DR   PDB; 2QCJ; X-ray; 3.00 A; A/B=1-294.
DR   PDB; 2QCT; X-ray; 2.80 A; A/B=1-294.
DR   PDB; 3BRH; X-ray; 2.20 A; A/B=1-310.
DR   PDB; 3H2X; X-ray; 2.20 A; A=1-302.
DR   PDB; 3OLR; X-ray; 2.50 A; A/B/C/D=1-294.
DR   PDB; 3OMH; X-ray; 2.90 A; A/B/C/D=1-294.
DR   PDB; 4J51; X-ray; 2.30 A; A/B=1-303.
DR   PDB; 7AAM; X-ray; 2.15 A; C=787-807.
DR   PDBsum; 2P6X; -.
DR   PDBsum; 2QCJ; -.
DR   PDBsum; 2QCT; -.
DR   PDBsum; 3BRH; -.
DR   PDBsum; 3H2X; -.
DR   PDBsum; 3OLR; -.
DR   PDBsum; 3OMH; -.
DR   PDBsum; 4J51; -.
DR   PDBsum; 7AAM; -.
DR   AlphaFoldDB; Q9Y2R2; -.
DR   SMR; Q9Y2R2; -.
DR   BioGRID; 117604; 54.
DR   DIP; DIP-29953N; -.
DR   FunCoup; Q9Y2R2; 1371.
DR   MINT; Q9Y2R2; -.
DR   STRING; 9606.ENSP00000352833; -.
DR   BindingDB; Q9Y2R2; -.
DR   ChEMBL; CHEMBL2889; -.
DR   GuidetoPHARMACOLOGY; 3084; -.
DR   DEPOD; PTPN22; -.
DR   iPTMnet; Q9Y2R2; -.
DR   PhosphoSitePlus; Q9Y2R2; -.
DR   BioMuta; PTPN22; -.
DR   DMDM; 20139861; -.
DR   jPOST; Q9Y2R2; -.
DR   MassIVE; Q9Y2R2; -.
DR   PaxDb; 9606-ENSP00000352833; -.
DR   PeptideAtlas; Q9Y2R2; -.
DR   ProteomicsDB; 21761; -.
DR   ProteomicsDB; 22726; -.
DR   ProteomicsDB; 85874; -. [Q9Y2R2-1]
DR   ProteomicsDB; 85875; -. [Q9Y2R2-2]
DR   ProteomicsDB; 85876; -. [Q9Y2R2-3]
DR   ProteomicsDB; 85877; -. [Q9Y2R2-4]
DR   ProteomicsDB; 85878; -. [Q9Y2R2-5]
DR   Antibodypedia; 33846; 307 antibodies from 35 providers.
DR   DNASU; 26191; -.
DR   Ensembl; ENST00000460620.5; ENSP00000433141.1; ENSG00000134242.17. [Q9Y2R2-5]
DR   GeneID; 26191; -.
DR   KEGG; hsa:26191; -.
DR   UCSC; uc001edt.4; human. [Q9Y2R2-1]
DR   AGR; HGNC:9652; -.
DR   ClinPGx; PA33995; -.
DR   CTD; 26191; -.
DR   DisGeNET; 26191; -.
DR   GeneCards; PTPN22; -.
DR   HGNC; HGNC:9652; PTPN22.
DR   HPA; ENSG00000134242; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; PTPN22; -.
DR   MIM; 152700; phenotype.
DR   MIM; 180300; phenotype.
DR   MIM; 193200; phenotype.
DR   MIM; 222100; phenotype.
DR   MIM; 600716; gene.
DR   OpenTargets; ENSG00000134242; -.
DR   Orphanet; 397; Giant cell arteritis.
DR   Orphanet; 900; Granulomatosis with polyangiitis.
DR   Orphanet; 85410; Oligoarticular juvenile idiopathic arthritis.
DR   Orphanet; 85408; Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   Orphanet; 3437; Vogt-Koyanagi-Harada disease.
DR   VEuPathDB; HostDB:ENSG00000134242; -.
DR   eggNOG; KOG0789; Eukaryota.
DR   GeneTree; ENSGT00940000160958; -.
DR   InParanoid; Q9Y2R2; -.
DR   OrthoDB; 10253954at2759; -.
DR   PAN-GO; Q9Y2R2; 20 GO annotations based on evolutionary models.
DR   PhylomeDB; Q9Y2R2; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; Q9Y2R2; -.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   SignaLink; Q9Y2R2; -.
DR   SIGNOR; Q9Y2R2; -.
DR   Agora; ENSG00000134242; -.
DR   BioGRID-ORCS; 26191; 23 hits in 1184 CRISPR screens.
DR   ChiTaRS; PTPN22; human.
DR   EvolutionaryTrace; Q9Y2R2; -.
DR   GeneWiki; PTPN22; -.
DR   GenomeRNAi; 26191; -.
DR   Pharos; Q9Y2R2; Tchem.
DR   PRO; PR:Q9Y2R2; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9Y2R2; protein.
DR   Bgee; ENSG00000134242; Expressed in bone marrow cell and 118 other cell types or tissues.
DR   ExpressionAtlas; Q9Y2R2; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0019900; F:kinase binding; ISS:BHF-UCL.
DR   GO; GO:0004726; F:non-membrane spanning protein tyrosine phosphatase activity; IEA:InterPro.
DR   GO; GO:0016791; F:phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; ISS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IMP:UniProtKB.
DR   GO; GO:0032717; P:negative regulation of interleukin-8 production; IMP:UniProtKB.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0070433; P:negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903753; P:negative regulation of p38MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IMP:BHF-UCL.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:UniProtKB.
DR   GO; GO:0035644; P:phosphoanandamide dephosphorylation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:1902523; P:positive regulation of protein K63-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IMP:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of type II interferon production; IMP:UniProtKB.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0045088; P:regulation of innate immune response; IBA:GO_Central.
DR   GO; GO:0032817; P:regulation of natural killer cell proliferation; IDA:BHF-UCL.
DR   GO; GO:1901222; P:regulation of non-canonical NF-kappaB signal transduction; IMP:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IBA:GO_Central.
DR   CDD; cd14602; PTPc-N22; 1.
DR   FunFam; 3.90.190.10:FF:000045; Tyrosine-protein phosphatase non-receptor type 12; 1.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR047170; PTN12/18/22.
DR   InterPro; IPR047253; PTN22_cat.
DR   InterPro; IPR000242; PTP_cat.
DR   InterPro; IPR016276; PTPN22.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   PANTHER; PTHR45983; TYROSINE PHOSPHATSE N18, PUTATIVE-RELATED; 1.
DR   PANTHER; PTHR45983:SF1; TYROSINE-PROTEIN PHOSPHATASE NON-RECEPTOR TYPE 22; 1.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000930; PTPN8_PTPN22; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autophagy; Cytoplasm;
KW   Diabetes mellitus; Disease variant; Disulfide bond; Hydrolase; Immunity;
KW   Lipid metabolism; Phosphoprotein; Protein phosphatase;
KW   Proteomics identification; Reference proteome;
KW   Systemic lupus erythematosus.
FT   CHAIN           1..807
FT                   /note="Tyrosine-protein phosphatase non-receptor type 22"
FT                   /id="PRO_0000094775"
FT   DOMAIN          24..289
FT                   /note="Tyrosine-protein phosphatase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   REGION          676..700
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          724..746
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        227
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160,
FT                   ECO:0000255|PROSITE-ProRule:PRU10044"
FT   BINDING         227..233
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|Ref.20"
FT   BINDING         274
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|Ref.20"
FT   MOD_RES         35
FT                   /note="Phosphoserine; by PKC/PRKCD"
FT                   /evidence="ECO:0000269|PubMed:18056643"
FT   MOD_RES         449
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         635
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P29352"
FT   MOD_RES         684
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P29352"
FT   MOD_RES         692
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P29352"
FT   DISULFID        129..227
FT                   /evidence="ECO:0000269|PubMed:19371084"
FT   VAR_SEQ         124..250
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044428"
FT   VAR_SEQ         137..160
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039725"
FT   VAR_SEQ         181..203
FT                   /note="ETRTIYQFHYKNWPDHDVPSSID -> VSVILAHQTSLQNLFSQITPAHF
FT                   (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039726"
FT   VAR_SEQ         204..807
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039727"
FT   VAR_SEQ         251..305
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039728"
FT   VAR_SEQ         647..674
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:21044313"
FT                   /id="VSP_039729"
FT   VAR_SEQ         685..807
FT                   /note="ELHQDRSSPPPPLPERTLESFFLADEDCMQAQSIETYSTSYPDTMENSTSSK
FT                   QTLKTPGKSFTRSKSLKILRNMKKSICNSCPPNKPAESVQSNNSSSFLNFGFANRFSKP
FT                   KGPRNPPPTWNI -> GKNFSWL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10068674"
FT                   /id="VSP_005134"
FT   VAR_SEQ         788..807
FT                   /note="FANRFSKPKGPRNPPPTWNI -> MCVILLKS (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044429"
FT   VARIANT         201
FT                   /note="S -> F (moderately reduces phosphatase activity;
FT                   dbSNP:rs7416347)"
FT                   /evidence="ECO:0000269|PubMed:22952725"
FT                   /id="VAR_072629"
FT   VARIANT         263
FT                   /note="R -> Q (probable protective factor against SLE;
FT                   severely reduces phosphatase activity; dbSNP:rs33996649)"
FT                   /evidence="ECO:0000269|PubMed:18981062,
FT                   ECO:0000269|PubMed:21287672, ECO:0000269|PubMed:22952725"
FT                   /id="VAR_072630"
FT   VARIANT         266
FT                   /note="R -> W (severely reduces phosphatase activity;
FT                   dbSNP:rs72650670)"
FT                   /evidence="ECO:0000269|PubMed:22952725"
FT                   /id="VAR_072631"
FT   VARIANT         620
FT                   /note="R -> W (risk factor for T1D; risk factor for RA;
FT                   risk factor for SLE; risk factor for VTLG; probable
FT                   protective factor against Crohn disease; also found in
FT                   patients with Graves disease, Hashimoto thyroiditis and
FT                   Addison disease; affects CSK kinase binding; alters B cell
FT                   receptor signaling and memory B cell proliferation;
FT                   dbSNP:rs2476601)"
FT                   /evidence="ECO:0000269|PubMed:15004560,
FT                   ECO:0000269|PubMed:15208781, ECO:0000269|PubMed:15273934,
FT                   ECO:0000269|PubMed:15531553, ECO:0000269|PubMed:15719322,
FT                   ECO:0000269|PubMed:16015369, ECO:0000269|PubMed:16710414,
FT                   ECO:0000269|PubMed:19265110, ECO:0000269|PubMed:21044313,
FT                   ECO:0000269|PubMed:21287672, ECO:0000269|Ref.3,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_022605"
FT   MUTAGEN         35
FT                   /note="S->E: Loss of phosphorylation by PKC/PRKCD."
FT                   /evidence="ECO:0000269|PubMed:18056643"
FT   MUTAGEN         36
FT                   /note="T->E: No effect on phosphorylation by PKC/PRKCD."
FT                   /evidence="ECO:0000269|PubMed:18056643"
FT   MUTAGEN         129
FT                   /note="C->S: Decreases activity 2 fold."
FT                   /evidence="ECO:0000269|PubMed:19371084"
FT   MUTAGEN         231
FT                   /note="C->S: Decreases activity 7 fold."
FT                   /evidence="ECO:0000269|PubMed:19371084"
FT   CONFLICT        51..52
FT                   /note="KP -> NA (in Ref. 1; AAD00904/AAD00905)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="V -> G (in Ref. 2; AAD27764)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        147
FT                   /note="G -> V (in Ref. 2; AAD27764)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        240
FT                   /note="I -> IV (in Ref. 1; AAD00905)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        372
FT                   /note="A -> V (in Ref. 4; AK310570)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        420
FT                   /note="L -> P (in Ref. 2; AAD27764)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        742
FT                   /note="P -> S (in Ref. 2; AAD27764)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..16
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           21..40
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           47..50
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           52..55
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          59..62
FT                   /evidence="ECO:0007829|PDB:3OMH"
FT   HELIX           67..69
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          70..72
FT                   /evidence="ECO:0007829|PDB:4J51"
FT   TURN            80..83
FT                   /evidence="ECO:0007829|PDB:4J51"
FT   STRAND          86..92
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          95..102
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           110..119
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          124..127
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          131..133
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          135..137
FT                   /evidence="ECO:0007829|PDB:3BRH"
FT   STRAND          146..148
FT                   /evidence="ECO:0007829|PDB:2QCJ"
FT   STRAND          151..153
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          156..165
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          167..178
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          181..190
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          195..197
FT                   /evidence="ECO:0007829|PDB:2QCJ"
FT   HELIX           199..202
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           203..215
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          218..221
FT                   /evidence="ECO:0007829|PDB:3BRH"
FT   STRAND          223..226
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   STRAND          228..232
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           233..248
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           258..266
FT                   /evidence="ECO:0007829|PDB:2P6X"
FT   HELIX           276..301
FT                   /evidence="ECO:0007829|PDB:2P6X"
SQ   SEQUENCE   807 AA;  91705 MW;  1ABE8AE89C9D9FBF CRC64;
     MDQREILQKF LDEAQSKKIT KEEFANEFLK LKRQSTKYKA DKTYPTTVAE KPKNIKKNRY
     KDILPYDYSR VELSLITSDE DSSYINANFI KGVYGPKAYI ATQGPLSTTL LDFWRMIWEY
     SVLIIVMACM EYEMGKKKCE RYWAEPGEMQ LEFGPFSVSC EAEKRKSDYI IRTLKVKFNS
     ETRTIYQFHY KNWPDHDVPS SIDPILELIW DVRCYQEDDS VPICIHCSAG CGRTGVICAI
     DYTWMLLKDG IIPENFSVFS LIREMRTQRP SLVQTQEQYE LVYNAVLELF KRQMDVIRDK
     HSGTESQAKH CIPEKNHTLQ ADSYSPNLPK STTKAAKMMN QQRTKMEIKE SSSFDFRTSE
     ISAKEELVLH PAKSSTSFDF LELNYSFDKN ADTTMKWQTK AFPIVGEPLQ KHQSLDLGSL
     LFEGCSNSKP VNAAGRYFNS KVPITRTKST PFELIQQRET KEVDSKENFS YLESQPHDSC
     FVEMQAQKVM HVSSAELNYS LPYDSKHQIR NASNVKHHDS SALGVYSYIP LVENPYFSSW
     PPSGTSSKMS LDLPEKQDGT VFPSSLLPTS STSLFSYYNS HDSLSLNSPT NISSLLNQES
     AVLATAPRID DEIPPPLPVR TPESFIVVEE AGEFSPNVPK SLSSAVKVKI GTSLEWGGTS
     EPKKFDDSVI LRPSKSVKLR SPKSELHQDR SSPPPPLPER TLESFFLADE DCMQAQSIET
     YSTSYPDTME NSTSSKQTLK TPGKSFTRSK SLKILRNMKK SICNSCPPNK PAESVQSNNS
     SSFLNFGFAN RFSKPKGPRN PPPTWNI
//
